Preclinical evaluation of F-18 fluoroethyltriazolyl PEGstilbenes as potential PET imaging agents for Alzheimers disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/582402

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Alzheimer's disease (AD) is the most common form of dementia and is becoming am ever increasing burden to the health system due to the aging of our population. Amyloid plaques are considered the hallmark of AD and a technique for their detection in vivo would be a breakthrough, not only for the diagnosis of AD but also for the development of drugs against AD. Nuclear medicine can image tissue function non-invasively. This project aims to develop new imaging agents to improve diagnosis of AD.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2014

Funding Scheme: NHMRC Project Grants

Funding Amount: $673,238.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nuclear Medicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Alzheimer's disease | Dementia | Non-invasive, pathological diagnosis | beta amyloid | cognitive disorders | organic chemistry | positron emission tomography | radiolabeling

Related Links